HealthTech Growth Lessons from Flow Neuroscience

Flow Neuroscience has already put a big number on the board: 50,000+ people have used its depression treatment, and it’s now used by 600+ clinicians and hospitals across Europe. For a startup selling a regulated medical device that involves brain stimulation, that’s not “nice traction”—that’s a hard-won credibility milestone.

This matters in the UK right now because the NHS capacity problem isn’t abstract. Waiting lists, GP access pressure, and a stretched mental health workforce mean the system needs treatments that can safely move parts of care closer to home. Remote, evidence-backed mental health tools won’t fix everything, but they can reduce demand on face-to-face services and help people start treatment sooner.

Daniel Månssōn, co-founder of Flow Neuroscience, lays out a playbook that’s useful well beyond mental health. If you’re building a UK health startup—or marketing one—Flow is a strong case study in how to scale a clinical product without losing trust.

Flow’s core thesis is simple and bold: take well-studied neuroscience (tDCS), wrap it in medical-grade engineering, pair it with behaviour change therapy, and make it usable at home.

What Flow is selling (and why the packaging matters)

Flow isn’t “an app.” It’s a regulated treatment product made of two parts:

• A medically approved tDCS headset that stimulates the dorsolateral prefrontal cortex (a brain region involved in mood regulation)
• A therapy app covering evidence-based behavioural interventions (sleep, nutrition, exercise, meditation)

That bundling is a marketing decision as much as a product decision.

The lesson: market an outcome, not a modality

Most HealthTech startups lead with the tech: “AI-powered,” “wearable,” “digital therapeutic,” “neuromodulation.” Flow leads with a problem: depression treatment access.

In practical marketing terms, this changes your messaging hierarchy:

1. Outcome: meaningful improvement within weeks
2. Context: usable at home, alongside existing care
3. Mechanism: tDCS + behavioural therapy
4. Proof: clinical/regulatory status + real-world usage

Flow reports ~77% of users see meaningful improvement within three weeks, and 50%+ are free from depression after ten weeks (as described in the interview). Whether you’re in neurotech or not, note what they’re doing: they’re anchoring growth around time-to-benefit and measurable outcomes, not features.

Where this connects to NHS reform

For the “Healthcare & NHS Reform” series, the key point is this: home-based treatments that are evidence-backed can shift demand away from scarce clinical time.

If a product can help a patient improve with less frequent clinician contact—or help them start treatment while waiting for therapy—it can support:

• Reduced pressure on community mental health teams
• Fewer avoidable escalations to higher-intensity services
• Better continuity of care through relapse-prevention behaviours

That’s the promise. But it only works if the product is trusted.

Credibility is the growth constraint (especially in brain tech)

Daniel says the biggest challenge has been credibility, which is exactly right. In UK HealthTech marketing, credibility isn’t a nice-to-have—it’s your main distribution channel.

The lesson: treat evidence like a product feature

Flow’s approach—clinical trials, regulatory approvals, ongoing data collection—shouldn’t sit in a “Science” tab that nobody reads. It should be integrated into the funnel.

Here’s what that looks like for a scaling HealthTech startup:

• Top-of-funnel: simple claims that are defensible (avoid exaggerated promises)
• Mid-funnel: clear summaries of clinical evidence, who it’s for, who it’s not for
• Bottom-of-funnel: clinician endorsements, safety guidance, onboarding support
• Post-purchase: adherence support, outcomes tracking, and follow-up content

A useful rule I’ve found: if your product has a clinical claim, your marketing team should know the evidence as well as the product team does.

Regulatory status is marketing—but don’t oversell it

Flow positions itself as the first medically certified tDCS device for home use in the UK and EU (per the interview). That’s a strong trust signal.

But great HealthTech marketing also makes room for nuance:

• Certification doesn’t mean “works for everyone.”
• It does mean the company has met safety/quality requirements and can be held accountable.

That balance—confident but careful—builds the kind of trust that survives scrutiny from clinicians, procurement teams, and skeptical patients.

Scaling responsibly: the unsexy work that wins contracts

Flow’s growth numbers are impressive, but what’s more interesting is how Daniel frames scaling: manufacturing safely, clinical support, correct usage.

That’s the real barrier between “a product that can sell online” and “a product that can fit into mainstream care pathways.”

The lesson: scale your operations before you scale your ads

A lot of startups in digital health pour budget into acquisition and only later discover the hidden bottleneck: onboarding, support, and adherence.

If you want NHS integration—or even just strong outcomes—build a scaling checklist early:

1. Onboarding that prevents misuse (especially important for devices)
2. Clinician-ready materials (contraindications, protocols, FAQs)
3. Patient adherence system (reminders, progress feedback, habit loops)
4. Safety escalation routes (what happens if a user deteriorates)
5. Real-world data pipeline (outcomes you can report credibly)

This isn’t red tape. It’s what makes growth durable.

Why adherence is a marketing metric

In mental health, outcomes depend heavily on consistency. If your product requires a structured programme (as many do), then adherence isn’t “customer success.” It’s the difference between:

• a product that generates positive case studies and clinician advocacy, and
• a product that creates disappointed users and reputational risk

If you’re measuring CAC and LTV, measure adherence too. It will predict both.

Three growth strategies from Flow that other UK startups can copy

Flow’s interview reads like a direct answer to a question many founders ask: How do you grow when you can’t hype?

Here are three strategies worth stealing.

1) Build at the intersection of disciplines

Flow started because a clinical psychologist and a computational neuroscientist/engineer combined perspectives.

The growth angle: interdisciplinary founding teams tend to create products with fewer “blind spots” (clinical validity, usability, safety engineering, and messaging clarity).

If you’re hiring, prioritise:

• a clinical lead who can defend claims
• an engineer who can ship reliably
• a marketer who can communicate without exaggeration

In UK HealthTech, this trio beats a “growth hacker” every day of the week.

2) Make the product work with the system, not against it

Flow can be used alone or alongside medication and therapy (per the interview). That positioning matters.

Healthcare procurement and clinicians don’t want tools that declare war on current pathways. They want tools that:

• reduce workload
• improve outcomes
• are safe and auditable

If you’re targeting NHS partnerships, your messaging should explicitly answer:

• Where does this fit in a stepped-care model?
• Who monitors the patient, and how?
• What’s the clinician workload impact?

3) Use credibility to open distribution

Flow’s reported usage by 600+ clinicians and hospitals isn’t just social proof—it’s distribution. Clinicians refer, institutions standardise, and systems scale.

A practical B2B2C funnel for regulated HealthTech often looks like:

• win a clinician champion
• support outcomes in a defined patient cohort
• publish/communicate results responsibly
• expand within the organisation
• then amplify to wider audiences

This is slower than pure DTC. It’s also harder to copy.

People also ask: what does this mean for NHS mental health capacity?

Can home-based neuromodulation reduce NHS waiting lists?

It can reduce pressure, but only if it’s integrated safely. A home-based treatment may help some patients start support earlier, potentially reducing deterioration while waiting for therapy. It won’t replace specialist services.

What would NHS integration require?

For a company like Flow, integration typically means:

• clear patient selection criteria
• clinician training and oversight models
• procurement-friendly evidence packs (clinical + economic)
• data governance and monitoring

Daniel mentions working with systems like the NHS to integrate Flow into mainstream pathways, which is exactly where HealthTech is heading in 2026.

Is this a marketing story or a clinical story?

It’s both. In regulated healthcare, marketing is the translation layer between evidence and adoption. The companies that win are the ones that can communicate clinical truth clearly—without blurring into hype.

What to take from Flow if you’re marketing a UK HealthTech startup

Flow Neuroscience’s growth isn’t luck, and it isn’t vibes. It’s the result of doing three things most startups avoid because they’re hard: build evidence, earn trust, and scale responsibly.

If you’re working on products that support NHS reform—reducing waiting lists, modernising care delivery, and improving long-term sustainability—Flow offers a useful north star: make it easier for patients to access help early, and make it easier for clinicians to say “yes” without taking on extra risk.

The next wave of UK health innovation won’t be won by the loudest brands. It’ll be won by the clearest ones—the teams that can prove what works, explain it plainly, and integrate into real care.

What would change in your go-to-market plan if you treated credibility as your primary growth channel rather than a compliance checkbox?